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Truvada is an antiretroviral (ARV) pill that combines two ARV drugs, 
tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), and 
has well-established efficacy in reducing the risk of contracting HIV 
if taken daily. Data from the South African (SA) Human Sciences 
Research Council show that women aged 15 - 25 years are most at 
risk of contracting HIV.[1] This report appears to have been one of 
the catalysts in prompting the Higher Education and Training HIV/
AIDS Programme (HEAIDS) and the National Department of Health 
to roll out Truvada to university and college students, because of the 
overlap with this high-risk age group. It is important to note that 
many studies with Truvada and preventive vaginal gels, involving 
thousands of women, have failed in SA and other Southern African 
Development Community countries.[2,3] These studies include trials 
such as FACTS and VOICE,[4-6] and it is thought that failure was due 
to lack of adherence and not ineffectiveness. The roll-out of Truvada 
therefore aims to offer protection to students at risk of HIV infection, 
in the hope that they will have better adherence, and has been 
extended to HIV-negative students across nine institutions of higher 
learning across SA. According to the director of HEAIDS, university 
students represent a group in which high rates of transactional sex 
occur, coupled with a low uptake of condoms (HEAIDS press release, 
27 September 2017).
It has been noted that transactional sex with so-called ‘sugar 
daddies’/‘blessers’ is a significant risk factor and social driver in 
the context of HIV infection among young people.[7] Relationships 
marked by age and material differences are increasingly common 
among university students and may involve exposure to unsafe sexual 
practices, among other things.[8] Truvada intervention will empower 
mostly young women to be in control of their infection status, as 
HIV prevalence and incidence rates remain disproportionately 
higher in females than in males.[9] However, as much as Truvuda is 
a potentially useful intervention, little is known about the drivers 
of product acceptability to end-users of such methods for HIV 
prevention. In a study that explored the end-user’s product preference 
for multipurpose prevention technology delivery forms in SA and 
Kenya, it was found that only 27% of women aged 18 - 30 years 
preferred the Truvada.[10] This is the age group into which most of 
the college and university students who are the target for Truvada 
roll-out fall. It is evident that we need to ask some questions: (i) is 
there sufficient evidence that college and university students will 
have better adherence than participants enrolled in previous studies 
in this country? (ii) since one of the drivers of uptake and adherence 
is perception of HIV risk, how certain are we that the college and 
university students perceive their risk as high? and (iii) lastly, as 
evidence shows that pre-exposure prophylaxis (pre-EP) is more likely 
to succeed if its roll-out is combined with interventions that target 
social drivers of HIV vulnerability specific to college and university 
students, will such interventions also be rolled out?
There has been particular interest in Truvada since announcement 
of the roll-out, owing to its effectiveness profile. There is no doubt 
that if it is taken correctly, with optimal adherence, there is a huge 
potential to reduce numbers of new infections, estimated as more 
than 250 000 in the year 2016.[11] What this article seeks to highlight 
is that, despite the many positives, we should also be aware of 
possible surprises consequent to Truvada roll-out in healthy, HIV-
negative young people. These are some of the questions we need 
to ask: (i) what are the possible effects of non-compliance with 
Truvada? (ii) what would be the consequences to participants who 
start off negative and are then infected, but continue to take Truvada 
intermittently? (iii) what are the possibilities of inducing resistance 
to Truvada in this young sexually active population? and (iv) what 
effect is Truvada pre-EP likely to have on attitudes of sexually 
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active people to other sexually transmitted diseases or infections? 
Furthermore, how prepared is our healthcare system to handle and 
manage the multifaceted challenges that will potentially arise from 
the roll-out in the nine institutions? Massive simultaneous roll-out of 
awareness programmes to educate on possible consequences of non-
adherence, and training of healthcare practitioners to handle this new 
phenomenon of Truvada preEP, are necessary.
Possible long-term effects
It is important to note that both TDF and FTC have documented 
adverse effects (adverse drug reactions, or ADRs). A meta-analysis 
by Siemieniuk et al.[12] showed that TDF/FTC was associated with 
stillbirth/early neonatal death and early premature delivery in HIV-
positive participants, although there were no data on HIV-negative 
participants. Several studies have reported that another effect of the 
two drugs is lowering bone mineral density,[13,14] so an additional 
concern is the possible long-term effects of Truvada pre-EP on 
the general health of the population. Surveillance of ADRs and 
related toxicities remains a challenge in the public health sectors of 
developing countries,[15] mainly owing to lack of coherent structures 
or systems for pharmacovigilance and drug surveillance that track, 
assess and monitor safety profiles of ARVs. Patients on ARV therapy 
(ART) are usually monitored through a spontaneous surveillance 
method that is currently inefficient in detecting ADRs.[15] In resource-
limited health sectors like that of SA, pre-EP for healthy individuals 
will compete for scarce resources that are failing to contain a 
growing disease burden.
What about the cost?
In September 2016, SA started to implement the World Health 
Organization (WHO) evidence-based guidelines for universal test 
and treat (UTT). This strategy aims to test 90% of infected people, 
treat 90% of those tested, and have viral loads suppressed in 
90% of individuals treated. SA already has one of the biggest 
ART programmes in the world, mostly funded by the fiscus, and 
implementation of UTT will significantly increase the number of 
people on ART. An increase in the budget will therefore be required 
in an already unfavourable economic climate. UTT will undoubtedly 
push demand for healthcare services in a context of a double burden 
of disease, high demand for medical personnel, and inadequate 
infrastructure. Public hospitals are already barely coping with the 
influx of patients, with complaints including medication stock-outs 
and sluggish financial support from donors, whose contribution has 
flatlined for the past 6 years.[16] To add a huge number of sexually 
active but healthy people to this overburdened healthcare platform 
would hasten its further deterioration.
TDF has been associated with severe nephrotoxicity, changes 
in markers of renal function, serious renal adverse events, and 
decreases in bone mineral density.[17] It should also be taken into 
consideration that most data on TDF ADRs are from controlled trials 
in populations that are genetically different from much of SA’s student 
population. Furthermore, many individuals in resource-limited 
settings use a dual system of healthcare, traditional and conventional. 
With an estimated 26.6 million users of traditional medicine in SA,[18] 
new drug-herb interactions are likely to emerge.
The challenges that policies such as UTT pose for developing 
countries have been well outlined, and have been predicted for 
sub-Saharan Africa (SSA).[19,20] The same challenges outlined by 
Bigna and colleagues[19,20] are applicable in the roll-out of Truvada to 
healthy individuals in SA. It was concluded that SSA cannot afford 
UTT, and in this case it is our submission that SA cannot afford 
the cost and implications of Truvada roll-out. SSA should always 
strategise in implementing WHO policies, factoring in local resource 
constraints. [19] We do not want to believe that Truvada roll-out is 
influenced by pharmaceutical companies that stand to gain regardless 
of the consequences to the country.
There is no doubt that Truvada roll-out will require additional 
resources, so for a successful outcome, funds need to be made 
available in a sustainable manner. Total health expenditure is 
predicted to reach almost 10% of the gross domestic product in 
SA by 2017/18, amounting to a staggering USD12 billion (ZAR178 
billion).[21] In the 2017 budget, the SA National Treasury allocated 
an additional USD63 million (ZAR885 million) to the response to 
HIV, in particular the implementation of UTT.[22] However, SA still 
faces a flood of new HIV infections, with an estimated 266 618 in 
2016.[11]
Conclusion
Generally, ART has been associated with ADRs, and exposing 
healthy individuals to Truvada could put them at risk of renal failure 
and other complications.[20] It is our opinion that, as we look at the 
positive side of Truvada roll-out, due care should be taken in its 
implementation, as there are environmental and genomic factors 
specific to SA populations. We write this letter in the hope that as the 
Truvada pre-EP programme is rolled out, appropriate preparations 
are made to ensure its success and possible mitigation measures put 
in place to ameliorate the negatives.
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